#USA #New York #Lucid Diagnostics #EsoGuard #GERD

Lucid Diagnostics Engages in Upcoming Investor Conferences

Lucid Diagnostics Inc., publicly traded under Nasdaq: LUCD, has made headlines with its recent announcement regarding participation in significant investor conferences set for August 2025. As a company at the forefront of cancer prevention medical diagnostics, Lucid aims to promote awareness and understanding of its groundbreaking contributions to the healthcare sector.

Conference Details

The company will attend the 10th Annual Needham Virtual MedTech Diagnostics 1x1 Conference on August 11-12, 2025. This virtual conference format allows for personalized meetings between Lucid's management and potential investors, fostering deeper conversations about the company's innovative approaches and future plans.

Additionally, Lucid will host a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference on August 13, 2025, at 2:30 PM ET in Boston, MA. This session will provide insights into the company's strategic direction, technological advancements, and market opportunities in cancer diagnostics.

About Lucid Diagnostics

Lucid Diagnostics stands out in the medical field, particularly through its focus on patients suffering from gastroesophageal reflux disease (GERD), often referred to as chronic heartburn. The company’s flagship product, the EsoGuard® Esophageal DNA Test, represents a milestone in early cancer detection. The test is uniquely designed to identify precancerous changes in the esophagus, allowing for timely intervention and potentially saving lives.

The EsoGuard test, combined with Lucid's EsoCheck® Esophageal Cell Collection Device, enables a simple, non-invasive procedure to collect samples. This pioneering approach not only facilitates early detection of esophageal precancer but also aligns with Lucid’s mission of minimizing cancer-related morbidity and mortality.

Connecting with Investors

Lucid Diagnostics invites interested parties to engage in its upcoming events, emphasizing its commitment to transparency and investor relations. During the Canaccord fireside chat, attendees will have the opportunity to learn about the company’s ongoing research, product development, and strategic initiatives that position it as a leader in the healthcare diagnostics market.

The archived versions of these presentations will be accessible through the Investor Relations section of the Lucid Diagnostics website for those unable to attend live. In this way, the company ensures that all stakeholders have access to valuable information about its operations and potential growth.

Conclusion

Participation in investor conferences notably enhances Lucid Diagnostics' profile within the healthcare community and financial markets, signaling its robust growth potential. With a focus on critical medical technology and patient care, Lucid is poised to make significant contributions to cancer prevention and treatment strategies. As the company gears up for these conferences, its innovative spirit and commitment to improving patient outcomes are set to take center stage.

For those keen on learning more about Lucid Diagnostics, please visit www.luciddx.com and explore information regarding its parent company PAVmed at www.pavmed.com.